Pfizer, in a rare COVID-19 setback, dumps Paxlovid’s intravenous sibling to leave ACTIV-3 future in doubtnews2022-02-08T13:06:58+00:00February 8th, 2022|FierceBiotech|
Pfizer, in a rare COVID-19 setback, dumps Paxlovid’s intravenous sibling in further blow to ACTIV-3news2022-02-08T13:06:58+00:00February 8th, 2022|FierceBiotech|
Bristol Myers Squibb doles out $8M in new grants to improve health equity with cardiovascular, oncology focusnews2022-02-08T03:55:22+00:00February 8th, 2022|FierceBiotech|
Congruence pulls in $50M series A to build a team of ‘drug hunters’ to go after rare disease targetsnews2022-02-07T19:40:41+00:00February 7th, 2022|FierceBiotech|
CVS to bring late-stage clinical trials to certain locations in push to serve underrepresented patientsnews2022-02-07T15:04:37+00:00February 7th, 2022|FierceBiotech|
Boundless Bio lures Berkley from Ionis to support clinical pushnews2022-02-07T14:01:30+00:00February 7th, 2022|FierceBiotech|
CANbridge, targeting gaps in AstraZeneca’s rare disease coverage, posts early-phase data on C5 inhibitornews2022-02-07T13:02:11+00:00February 7th, 2022|FierceBiotech|
Takeda joins Novartis and Merck in $45M funding for Koneksa Healthnews2022-02-04T18:13:24+00:00February 4th, 2022|FierceBiotech|
Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck’s drugnews2022-02-04T17:45:09+00:00February 4th, 2022|FierceBiotech|
Sanofi ends two phase 1 cancer assets weeks after axing Sangamo dealnews2022-02-04T16:31:29+00:00February 4th, 2022|FierceBiotech|
